Study Objective. To standardize treatment of alcohol withdrawal syndrome (AWS) in internal medicine patients using an adult AWS practice guideline with a symptom-triggered management approach. Design. Prospective interventional (pilot group) and retrospective (control group). Setting. University teaching hospital. Patients. Thirty-two internal medicine patients identified as being at risk for AWS and treated according to the AWS practice guideline who were compared with 49 internal medicine patients managed with nonstandardized approaches. Intervention. Patients in the pilot group were assessed using the AWS type indicator. They received lorazepam, clonidine, or haloperidol, based on AWS type indicator assessment and adult AWS practice guideline criteria. Measurements and Main Results. Data collected and analyzed were drugs administered to control AWS symptoms, use of sitters and physical restraints, length of hospital stay, and discharge from hospital receiving tapered drug therapy. Pilot patients received 46.6% less benzodiazepine (p=0.001), 20% more clonidine (p=0.01), and 18.2% more haloperidol (p=0.002) than control patients. No drug therapy was required in 19% of pilot patients compared with 2% of controls (p=0.01). Significantly more control (71.4%) than pilot patients (18.8%) were discharged with tapered benzodiazepine therapy (p≤0.01). No significant differences were found between groups for sitters, restraints, or hospital length of stay. Conclusion. This pilot project suggests that internal medicine patients at risk for AWS can be managed with a standardized, symptom-triggered approach using decreased amounts of benzodiazepine in combination with adjunctive agents to treat adrenergic hyperactivity and delirium. Further data are necessary to determine the impact of the practice guideline on patient outcome measurements. Key Words: alcohol withdrawal syndrome, benzodiazepines, clonidine, haloperidol, practice guideline. Concerns about the frequent occurrence of alcohol withdrawal syndrome (AWS) in patients treated at our university teaching hospital prompted the formation of a performance improvement team to examine reports in the literature regarding evidence-based practice 1 and make recommendations to improve patient management and outcomes. A comprehensive description of the original project developed and implemented by the performance improvement team was published previously.
treatment of AWS.
The AWS typology 5 method of treatment postulates that AWS is a heterogeneous syndrome that has been misunderstood as a single condition, previously classified from mild to severe. This methodology suggests that AWS consists of three distinct symptom clusters, each with its own physiologic basis and preferred treatment agents. The AWS type indicator is used to assess patients identified as being at risk for AWS (Figure 1 ). This instrument categorizes AWS into three distinct symptom clusters: type A (central nervous system excitation), type B (adrenergic hyperactivity) and type C (delirium). Type A symptoms are treated with the benzodiazepine lorazepam. Type B symptoms not adequately controlled by lorazepam are treated with the central ␣-adrenergic agonist clonidine. Type C symptoms and severe agitation 6 are treated with the neuroleptic haloperidol.
The adult AWS practice guideline was originally developed for use with specific surgical populations at our institution. It was revised for internal medicine patients based on feedback from previous users of the guideline and the internal medicine attending physicians. Modifications involved changing the frequency of assessment using the AWS type indicator from every hour to every 2 hours, and changing the initial order for lorazepam from 2 mg every hour as needed to 1-2 mg every hour as needed. The revised practice guideline was reviewed and approved for implementation by the institutional review board.
The purpose of this project was to assess the AWS typology method of treatment used for internal medicine patients. We hypothesized that a standardized symptom-triggered approach to managing AWS in these patients would decrease the use of benzodiazepine, increase the use of adjunctive drugs to manage adrenergic hyperactivity and delirium, decrease the need for sitters and physical restraints, and reduce hospital length of stay (LOS) without increasing adverse events.
Methods
Inclusion criteria for patients eligible to be in the pilot group (i.e., those treated according to the practice guideline) were admission to the internal medicine service and at least one of the following: a score of at least 2 on the CAGE (cut down, annoyed by criticism, guilty about drinking, eye-opener drinks) questionnaire, 7 heavy daily alcohol intake (> 6 drinks), history of AWS, or history of AWS-related seizures. Control patients were identified by documentation in their medical record of a discharge diagnosis of alcohol withdrawal, or therapy with a combination of benzodiazepine, thiamine, folic acid, and multivitamin. A benzodiazepine and these vitamin supplements are commonly prescribed in our hospital for patients with suspected or known alcohol abuse. The controls were patients discharged from the internal medicine service during the 6-month period preceding practice guideline education and implementation. Excluded from the control group were patients treated with oral or intravenous alcohol and those whose medical records were incomplete.
Education about AWS and use of the practice guideline was provided to nurses, physicians, and pharmacists of the pilot unit. The psychiatric consultation liaison nurse and the clinical pharmacy specialist provided initial and continuing education sessions and support to the pilot unit staff. The order sets required to implement the practice guideline were made available through the medical center's Intranet. The AWS flow sheet used for assessment and documentation was available on the pilot unit. The flow sheet includes the AWS type indicator (Figure 1 ), the nursing documentation form (Figure 2) , and the adult AWS practice guideline algorithms ( Figures  3 and 4) .
Data Collection
Data collection involved patient demographics (age, sex, race or ethnicity), information about hospitalization (principal diagnosis, admission unit, attending physician), pertinent medical history (comorbid substance abuse, previous AWS, alcohol-related seizures), information about alcohol intake (daily consumption based on patient report and confirmed by family or friends, intoxication at admission, CAGE score for pilot patients), alcohol withdrawal symptoms (type A, B, and C symptoms) in pilot patients, adverse events (withdrawal seizures, cardiovascular events, transfer to intensive care unit), and treatment outcomes (amount of drug administered, use of sitters or restraints, hospital LOS, tapered drug therapy at discharge).
Statistical Analysis
Continuous data were assessed using a 2-tailed t test; nominal data were assessed using a principal diagnosis, and a combined ICD-9 code related to alcohol abuse. The data to construct this variable came from the South Carolina hospital discharge data set. To control for possible selection bias, LOS was transformed and analyzed using the Heckman transformation.
Oxazepam was frequently used to treat patients in the comparison group. To facilitate comparison with the pilot group, all doses were converted to lorazepam equivalents using a 15:1 conversion factor.
Results
A total of 81 internal medicine patients (32 pilot, 49 control) were included in the data analysis. The pilot and control groups did not differ significantly with respect to mean age and race or ethnicity. Significantly more men were in the control group than in the pilot group (p=0.02; Table 1 ).
Pilot patients received significantly less lorazepam (p=0.001) and significantly more clonidine (p=0.01) and haloperidol (p=0.002) than controls. Significantly more pilot patients (19%) than controls (2%) required no drug therapy to manage or prevent symptoms of alcohol withdrawal (p=0.01). Excluding these patients from the analysis of amount of drug administered did not change the statistical significance of these findings. Significantly more controls (71.4%) than pilot patients (18.8%) were discharged with tapered benzodiazepine therapy (p<0.01; Table 2 ). Pilot and control groups did not differ significantly with respect to adverse events. One patient in each group experienced an alcohol withdrawal seizure (p=0.76). A 12-lead electrocardiogram (ECG) was documented for 18 (56%) pilot patients before haloperidol therapy was begun and for 29 (59%) controls during their hospital stay. In these patients, a prolonged QTc interval (> 450 msec) was noted in 13 (72%) pilot patients and eight (28%) controls (p=<0.01). No patients experienced cardiovascular events or were transferred to an intensive care unit. A sitter was needed for one pilot patient (3%), whereas the comparison group required a sitter for six (12%) patients (p=0.23). Use of restraints was similar for both groups-nine (28%) pilot patients and 13 controls (27%) (p=0.87). No significant differences between groups were found for LOS. Multivariate analysis of LOS (controlling for expected LOS, age, race or ethnicity, and sex) and analysis of the data using the Heckman transformation to control for possible selection bias confirmed no difference in the LOS between groups (Table 3) .
Discussion
Pilot patients were evaluated based on clusters of symptoms representing the manifestations of AWS. The newly introduced practice guideline provided a plan for management before the emergence of more severe AWS. The plan involved administration of three different classes of drugs-benzodiazepine, central ␣-adrenergic agonist, and neuroleptic-based on patientspecific symptoms. Retrospective review revealed that the control patients were treated with nonstandardized approaches that did not include assessment with a validated instrument to accurately identify and categorize AWS symptoms. These patients typically were given a scheduled dose of a benzodiazepine regardless of symptoms. This practice contributed to higher benzodiazepine consumption in the control group. Unnecessary benzodiazepine administration can result in suppressed cognition and decreased mental acuity that may be incorrectly attributed to other medical conditions and may mask pain. These patients may also have an increased risk for falls and decreased ability to participate in patient care activities.
The lower benzodiazepine consumption in pilot patients may have been related to regularly scheduled assessments with the AWS type indicator, symptom-triggered drug administration, and adjunctive therapy with clonidine and haloperidol based on symptoms. The physician practice of treating symptoms of delirium in the control patients with benzodiazepine rather than an adjunctive neuroleptic may also have contributed to the control group's higher benzodiazepine intake. Although identified as being at risk for AWS, six (19%) pilot patients and one (2%) control patient required no drug (p=0.01). Experience using the practice guideline with regular symptom assessment has illustrated the difficulty in predicting which patients will develop AWS. Some patients who reported heavy daily alcohol consumption for an extended period, but no previous AWS, did not exhibit symptoms or require drug therapy.
More than 70% of control patients were discharged from the hospital receiving tapered benzodiazepine therapy. This practice may be dangerous because of the potential for this patient population to combine benzodiazepine and alcohol after discharge. The practice was avoided for the pilot patients, most of whose benzodiazepine therapy was tapered off before discharge without a significant increase in LOS.
No significant adverse events were noted in either the pilot or the control group. The possibility of neuroleptic-induced QTc interval prolongation was a concern that prompted an order for a 12-lead ECG before the start of haloperidol in the pilot group. Seventy-two percent of pilot patients and 28% of controls had a prolonged QTc of 450 msec or greater. Because of the possible complication of torsade de pointes, haloperidol therapy was avoided in pilot patients with a prolonged QTc interval. Every effort should be made to perform an ECG at hospital admission for any patient at risk for AWS. This is especially important for internal medicine patients who tend to have numerous medical problems and a complicated drug regimen that may include other drugs known to prolong the QTc interval. 8 No between-group differences were found regarding the main outcome measurements. Hospital LOS between groups did not differ significantly, although a trend was seen toward an increased LOS in the pilot group (p=0.07).
When patients who received no drug therapy were excluded from this analysis, the trend diminished (p=0.13). As stated earlier, there was a tendency to complete tapered drug therapy in pilot patients before discharge. This practice suggests an emphasis on patient care that views AWS as a significant health risk and resists the current trend to discharge patients as soon as their initial admitting problem has been resolved.
Limitations
Nonrandomized inclusion of patients in each group may have introduced selection bias to this performance improvement project. A few patients who were eligible for the pilot group may not have been included due to physician preference. The small sample size and resultant power limited analysis of the outcome measurements.
Before initiation of this pilot project, which was endorsed by the interdisciplinary staff of the internal medicine unit, extensive education was provided to the attending and resident physicians, pharmacists, and nursing staff about AWS and the adult AWS practice guideline. Even with this careful planning, however, some barriers to implementation were encountered. Monthly rotation of three teams of internal medicine residents made the provision of continuing resident education regarding use of the practice guideline a challenge. The regular nursing staff of the pilot unit supported the project, but the frequent use of float nurses unfamiliar with the practice guideline contributed to implementation inconsistencies and posed a challenge for nursing education.
Future Directions
Results of this project and the previous project with surgery patients 2 have generated interest in symptom-triggered AWS assessment and treatment throughout our hospital. The plan to establish a consistent method for managing AWS in all adult patient care areas has been embraced by the new hospitalist physician group, whose practice was established after completion of the internal medicine pilot project. A new AWS work group was formed to begin revising the adult AWS practice guideline for implementation in all adult patient care areas. This group consisted of four members of the original AWS management performance improvement team, one hospitalist physician, and three physician consultants specializing in addiction.
After reviewing the results of the two projects, the work group decided to continue using the AWS typology method of assessment and treatment, including the AWS type indicator and the adult AWS flow sheet. The work group suggested minimal revision of the adult AWS practice guideline algorithms. The format of the physician order set (Figures 5 and 6 ) was changed significantly to make it more userfriendly and consistent with the format of other standard order sets used throughout the hospital. The new orders include the option of scheduled lorazepam dosing for patients who have experienced an AWS seizure associated with their current hospitalization. The instruction section (Figure 4 ) of the revised adult AWS practice guideline contains information about using the anticonvulsive agent carbamazepine 9, 10 to treat AWS symptoms in patients with closed head injuries or other conditions in which benzodiazepines may cause confusion or disinhibition.
The revised practice guideline and physician order set were approved by the hospital forms committee and endorsed by the medical executive committee for hospitalwide implementation. To provide for a consistent method of education for the physicians, nursing staff, pharmacists, and social workers in all adult patient care areas, a four-module video program was developed and made available on the hospital intranet. Completion of a pretest and posttest is required of participants to aid in evaluating the effectiveness of this method of educating staff.
In July 2001, the Food and Drug Administration approved the clinical use of the percent carbohydrate-deficient transferrin (%CDT), a biologic test that detects excessive alcohol consumption. 11, 12 The %CDT laboratory test is the only one approved in the United States specifically for detection of heavy drinking. A %CDT of 2.6 or greater warns the clinician that the patient probably has been consuming four or more alcoholic drinks/day for 2 weeks or longer and may be at risk for AWS. This test is part of the revised adult AWS orders and is particularly helpful when information about daily alcohol intake cannot be obtained or the accuracy of the patient report is in question. When the %CDT test result is less than 2.6 and other clinical indicators of heavy drinking have been considered, use of the practice guideline may be discontinued. If the test result is 2.6 or greater, the practice guideline is continued. Test results can also be used by staff providing educational counseling to the patient, to emphasize the negative consequences of excessive drinking and stress the importance of accepting assistance with referral for treatment.
Conclusion
This pilot project suggests that internal medicine patients at risk for AWS can be managed with a standardized, symptom-triggered approach using decreased amounts of benzodiazepine in combination with adjunctive agents to treat adrenergic hyperactivity and delirium. Further data are necessary to determine the impact of the practice guideline on patient outcome measurements.
